Journal ArticleDOI
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Keertan Dheda,Tawanda Gumbo,Gary Maartens,Kelly E. Dooley,Ruth McNerney,Megan Murray,Jennifer Furin,Edward A. Nardell,Leslie London,Erica Lessem,Grant Theron,Paul D. van Helden,Stefan Niemann,Matthias Merker,David W. Dowdy,Annelies Van Rie,Annelies Van Rie,Gilman Kit Hang Siu,Jotam G. Pasipanodya,Camilla Rodrigues,Taane G. Clark,F. A. Sirgel,Aliasgar Esmail,Hsien-Ho Lin,Sachin R Atre,H. Simon Schaaf,Kwok Chiu Chang,Christoph Lange,Payam Nahid,Zarir F Udwadia,C. Robert Horsburgh,Gavin J. Churchyard,Gavin J. Churchyard,Dick Menzies,Anneke C. Hesseling,Eric L. Nuermberger,Helen McIlleron,Kevin P. Fennelly,Eric Goemaere,Ernesto Jaramillo,Marcus Low,Carolina Morán Jara,Nesri Padayatchi,Robin M. Warren +43 more
Reads0
Chats0
TLDR
Several lines of evidence suggest that alternative mechanisms-including pharmacokinetic variability, induction of efflux pumps that transport the drug out of cells, and suboptimal drug penetration into tuberculosis lesions-are likely crucial to the pathogenesis of drug-resistant tuberculosis.About:
This article is published in The Lancet Respiratory Medicine.The article was published on 2017-04-01. It has received 461 citations till now. The article focuses on the topics: Bedaquiline & Delamanid.read more
Citations
More filters
Journal ArticleDOI
Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.
Paul K. Drain,Kristina L. Bajema,David W. Dowdy,Keertan Dheda,Kogieleum Naidoo,Samuel G Schumacher,Shuyi Ma,Shuyi Ma,Erin W. Meermeier,David M. Lewinsohn,David R. Sherman,David R. Sherman +11 more
TL;DR: Current understanding of the pathogenesis, immunology, clinical epidemiology, diagnosis, treatment, and prevention of both incipient and subclinical TB, two emerging clinical states of an ancient bacterium are reviewed.
Journal ArticleDOI
A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
Paolo Miotto,Belay Tessema,Elisa Tagliani,Leonid Chindelevitch,Angela M. Starks,Claudia Emerson,Debra Hanna,Peter S. Kim,Richard Liwski,Matteo Zignol,Christopher Gilpin,Stefan Niemann,Claudia M. Denkinger,Joy Fleming,Robin M. Warren,Derrick W. Crook,Derrick W. Crook,James E. Posey,Sebastien Gagneux,Sebastien Gagneux,Sven Hoffner,Sven Hoffner,Camilla Rodrigues,Iñaki Comas,David M. Engelthaler,Megan Murray,David Alland,Leen Rigouts,Christoph Lange,Keertan Dheda,Rumina Hasan,Uma Devi Ranganathan,Ruth McNerney,Matthew Ezewudo,Daniela Maria Cirillo,Marco Schito,Claudio U. Köser,Timothy C. Rodwell,Timothy C. Rodwell +38 more
TL;DR: This study provides a standardised and comprehensive approach for the interpretation of mutations as predictors of M. tuberculosis drug- resistant phenotypes and has implications for the clinical interpretation of molecular diagnostics and next-generation sequencing as well as efficient individualised therapy for patients with drug-resistant tuberculosis.
Journal ArticleDOI
Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis
Olivier Van Der Meeren,Mark Hatherill,Videlis Nduba,Robert J. Wilkinson,Monde Muyoyeta,Elana van Brakel,Helen Ayles,German Henostroza,Friedrich Thienemann,Thomas J. Scriba,Andreas H. Diacon,Gretta L Blatner,Marie-Ange Demoitié,Michele Tameris,Mookho Malahleha,James C Innes,Elizabeth Hellstrom,Neil A. Martinson,Tina Singh,Elaine J Akite,Aisha Khatoon Azam,Anne Bollaerts,Ann M. Ginsberg,Thomas G. Evans,Paul Gillard,Dereck Tait +25 more
TL;DR: M72/AS01E provided 54.0% protection for M. tuberculosis–infected adults against active pulmonary tuberculosis disease, without evident safety concerns, in a phase 2b trial in Kenya, South Africa, and Zambia.
Journal ArticleDOI
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Simon Tiberi,Nelita du Plessis,Gerhard Walzl,Michael J. Vjecha,Martin Rao,Francine Ntoumi,Sayoki Mfinanga,Nathan Kapata,Peter Mwaba,Timothy D. McHugh,Giuseppe Ippolito,Giovanni Battista Migliori,Markus Maeurer,Alimuddin Zumla +13 more
TL;DR: The developmental pipeline and landscape of new and repurposed tuberculosis drugs, treatment regimens, and host-directed therapies (HDTs) for drug-sensitive and drug-resistant tuberculosis are reviewed and a range of HDTs and immune-based treatments are under investigation as adjunctive therapy.
Journal ArticleDOI
Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care
Navisha Dookie,Santhuri Rambaran,Nesri Padayatchi,Nesri Padayatchi,Sharana Mahomed,Kogieleum Naidoo,Kogieleum Naidoo +6 more
TL;DR: Advances in sequencing technology will help devise better molecular diagnostics for more effective DR-TB management enabling personalized treatment, and will facilitate the development of new drugs aimed at improving outcomes of patients with this disease.
References
More filters
Journal ArticleDOI
Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis
TL;DR: The short-course regimen has potential to substantially lessen the multidrug-resistant tuberculosis epidemic, but this effect depends on its long-term efficacy, its ability to expand treatment access, and the role of second-line drug resistance.
Journal ArticleDOI
'I'm fed up': experiences of prior anti-tuberculosis treatment in patients with drug-resistant tuberculosis and HIV.
Priti Kambli,Kanchan Ajbani,Chaitali Nikam,Archana Khillari,Anjali Shetty,Zarir F Udwadia,Sophia B. Georghiou,Timothy C. Rodwell,Antonino Catanzaro,Camilla Rodrigues +9 more
TL;DR: Phenotypically, gyrA mutations Ala90Val, Ser91Pro or Asp 94Ala showed a low level of resistance to LVX, while Asp94Asn/Tyr, Asp95Gly or As p94His mutations had high-level resistance.
Journal ArticleDOI
Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
Shashikant Srivastava,Chawanga Modongo,Chandima Wasana Siyambalapitiyage Dona,Jotam G. Pasipanodya,Devyani Deshpande,Tawanda Gumbo,Tawanda Gumbo +6 more
TL;DR: The optimal exposures and kill rates identified for log-phase M. tuberculosis will be optimal even for semidormant bacilli, and the EC90 is the dosing target for intermittent therapy that optimizes cure in TB programs for MDR-TB patients.
Journal ArticleDOI
Cavitary Penetration of Levofloxacin among Patients with Multidrug-Resistant Tuberculosis
Russell R. Kempker,Aline Bergesch Barth,Sergo Vashakidze,Ketino Nikolaishvili,Irina Sabulua,Nestani Tukvadze,Nino Bablishvili,Shota Gogishvili,Ravi Shankar Prasad Singh,Jeannette Guarner,Hartmut Derendorf,Charles A. Peloquin,Henry M. Blumberg +12 more
TL;DR: Optimizing serum concentrations will help ensure optimal cavitary concentrations of levofloxacin, which may enhance treatment outcomes and help optimize SLD dosing.
Journal ArticleDOI
The movement of multidrug-resistant tuberculosis across borders in East Africa needs a regional and global solution.
Kevin P. Cain,Nina Marano,Maureen Kamene,Joseph Sitienei,Subroto Mukherjee,Aleksandar Galev,John Wagacha Burton,Orkhan Nasibov,Jackson K. Kioko,Kevin M. De Cock +9 more
TL;DR: Kevin Cain and colleagues reflect on the cross border movement of people from Somalia with MDR-TB and the implications for MDRsTB programs in East Africa.
Related Papers (5)
A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
Paolo Miotto,Belay Tessema,Elisa Tagliani,Leonid Chindelevitch,Angela M. Starks,Claudia Emerson,Debra Hanna,Peter S. Kim,Richard Liwski,Matteo Zignol,Christopher Gilpin,Stefan Niemann,Claudia M. Denkinger,Joy Fleming,Robin M. Warren,Derrick W. Crook,Derrick W. Crook,James E. Posey,Sebastien Gagneux,Sebastien Gagneux,Sven Hoffner,Sven Hoffner,Camilla Rodrigues,Iñaki Comas,David M. Engelthaler,Megan Murray,David Alland,Leen Rigouts,Christoph Lange,Keertan Dheda,Rumina Hasan,Uma Devi Ranganathan,Ruth McNerney,Matthew Ezewudo,Daniela Maria Cirillo,Marco Schito,Claudio U. Köser,Timothy C. Rodwell,Timothy C. Rodwell +38 more
Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study.
Timothy M Walker,Thomas Kohl,Shaheed V. Omar,Jessica Hedge,Carlos del Ojo Elias,Phelim Bradley,Zamin Iqbal,Silke Feuerriegel,Katherine E. Niehaus,Daniel J. Wilson,David A. Clifton,Georgia Kapatai,Camilla L. C. Ip,Rory Bowden,Francis Drobniewski,Francis Drobniewski,Caroline Allix-Béguec,Cyril Gaudin,Julian Parkhill,Roland Diel,Philip Supply,Philip Supply,Derrick W. Crook,E. Grace Smith,A. Sarah Walker,Nazir Ahmed Ismail,Stefan Niemann,Tim E. A. Peto +27 more
Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
Maria Tarcela Gler,Vija Skripconoka,Epifanio Sanchez-Garavito,Heping Xiao,Jose L. Cabrera-Rivero,Dante E. Vargas-Vasquez,Mengqiu Gao,Mohamed A. Awad,Seung Kyu Park,Tae Sun Shim,Gee Young Suh,Manfred Danilovits,Hideo Ogata,Anu Kurve,Joon Chang,Katsuhiro Suzuki,Thelma E. Tupasi,Won-Jung Koh,Barbara J. Seaworth,Lawrence Geiter,Charles D. Wells +20 more
Rapid molecular detection of tuberculosis and rifampin resistance.
Catharina Boehme,Pamela Nabeta,Doris Hillemann,Mark P. Nicol,Shubhada Shenai,Fiorella Krapp,Jenny Allen,Rasim Tahirli,Robert Blakemore,Roxana Rustomjee,Ana Milovic,Martin Jones,Sean M. O'Brien,David H. Persing,Sabine Ruesch-Gerdes,Eduardo Gotuzzo,Camilla Rodrigues,David Alland,Mark D. Perkins +18 more